133P Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment
نویسندگان
چکیده
منابع مشابه
Immunotherapy in the treatment of non-small cell lung cancer.
Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulato...
متن کاملMaintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
A 53-years-old woman was diagnosed with lung adenocarcinoma state IV (synchronous pleural involvement) in April 2009. First-line systemic treatment included six cycles of Carboplatin, Paclitaxel, and Bevacizumab. Partial response was achieved. Maintenance therapy with Bevacizumab and Pemetrexed was given from September 2009 to February 2010. No response changes were observed. Immunotherapy was ...
متن کاملGemcitabine in non-small cell lung cancer: just another drug?
Lung cancer is the leading cause of cancer death in Mexico and most countries. This highly lethal malignancy remains as a great challenge to oncologists due to its aggressive tumor biology and poor sensitivity to radiation and chemotherapy. In addition, no screening strategies have shown benefit in terms of reducing its mortality. Consequently, most patients present with locally advanced diseas...
متن کاملImmunotherapy and the Treatment of Non–Small Cell Lung Cancer
W ith more than 200,000 cases expected for 2016, lung cancer is the leading cause of cancer death in both men and women, accounting for more than one-quarter of all cancer deaths. “A lot of people don’t realize that lung cancer has a higher mortality than breast, prostate, and colorectal cancers combined,” said Suzanne Walker, CRNP, MSN, AOCN®, BC, of Abramson Center at Penn Presbyterian Medica...
متن کاملImmunotherapy for Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide some benefit, there is a need for newer therapies for the treatment of patients with advanced NSCLC. Immunotherapy aims to augment the recognition of cancer as foreign, to stimulate immune respons...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: 1556-0864
DOI: 10.1016/s1556-0864(21)01975-4